APPENDIX IV

STATUTORY AND GENERAL INFORMATION

Patent

Applicant

Application

Application Number

Application Date

Place of

The Company

No.

10.

11.

12.

13.

Crystalline form of
(s)-7-(1-acryloylpiperidin
-4-yl)-2-(4-phenoxyphenyl)
-4,5,6,7-tetra-hydropyrazolo
[1,5-a]pyrimidine-3-carboxamide,
preparation, and uses
thereof
Treatment cancers using a
combination comprising btk
inhibitors
Anti-pd1 antibodies and
their use as therapeutics
and diagnostics
Immunotherapy for
hepatocellular carcinoma

WO

PCT/IB2017/054955

2017/08/15

WO

PCT/CN2017/098023

2017/08/18

US

US15/978,695

2013/09/13

WO

PCT/CN2018/092827

2018/06/26

BeiGene

Switzerland

The Company

BeiGene

Switzerland

Save as aforesaid, as of the Latest Practicable Date, there were no other trade or service marks,

patents, intellectual or industrial property rights which were material in relation to our business.

C.

FURTHER INFORMATION ABOUT OUR DIRECTORS

1.

Directors’ service contracts

See “Directors and Senior Management — Employee Agreements of Senior Management and
Technical Staff” for a discussion of the terms of employment of Mr. John V. Oyler as our Chief
Executive Officer.

We engage Dr. Xiaodong Wang as a consultant to provide us with scientific and advisory services

under a consulting arrangement. See “Connected Transaction”.

2.

Remuneration of Directors

See “Directors and Senior Management — Directors’ Remuneration” for a discussion of

Directors’ remuneration.

3.

Disclosure of interests

(a)

Interests and short positions of our Directors in the share capital of our Company and its
associated corporations following completion of the Global Offering

Immediately following completion of the Global Offering (assuming the Over-allotment Option
is not exercised and no Shares are issued pursuant to our Equity Plans), the interests and/or short
positions (as applicable) of our Directors and chief executives in the shares, underlying shares and

— IV-8 —

